Trials / Active Not Recruiting
Active Not RecruitingNCT04736485
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | perioperative treatment | FLOT + Spartalizumab |
Timeline
- Start date
- 2021-06-28
- Primary completion
- 2024-03-01
- Completion
- 2027-03-01
- First posted
- 2021-02-03
- Last updated
- 2026-04-14
- Results posted
- 2026-04-14
Locations
13 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04736485. Inclusion in this directory is not an endorsement.